UNSPSC 51172321: Deferiprone

This classification denotes a cancer tnm vessel invasion finding category with the molecular formula C7H9NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2BTY8KH53L, chemically known as 1,2-dimethyl-3-hydroxypyrid-4-one but generally known as deferiprone, which bears US NIH Compound Identifier 2972. European Medicines Agency schedules Deferiprone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06941MIG.

UNSPSC 51172321 Deferiprone is a Commodity code representing pharmaceutical products, but the recent state and local opportunities tagged under it show minimal alignment with deferiprone specifically—a chelating agent used to treat iron overload in patients with thalassemia. The three most recent solicitations posted between January and July 2026 span offender drug testing, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and OTC products, none of which target deferiprone as a named procurement. The code appears to receive sparse and misdirected activity in state and local procurement, with opportunities addressing broader pharmacy benefit management, cooperative purchasing of generics, and clinical specimen testing rather than specialty pharmaceutical procurement aligned with the code's nominal scope.

The issuing bodies include a county community supervision agency (Collin County, Texas), a state health commission (Texas HHS Commission), and a multistate cooperative purchasing alliance administered through Minnesota's Department of Administration, reflecting the fragmented nature of state and local pharmaceutical procurement across criminal justice, health services, and cooperative purchasing channels. The geographic activity centers on Texas and Minnesota with secondary reach into Oregon through the cooperative vehicle. The most concrete recent opportunity is Collin County's RFP 2026-327 for offender specimen collection and drug testing services (due July 23, 2026, with an estimated contract value of $600,000 and anticipated award August 10, 2026), which tests for controlled substances rather than sourcing deferiprone or related chelating agents. The Minnesota MMCAP RFP S1070000015802 (due March 26, 2026) procures generic pharmaceuticals and OTC products through authorized wholesalers but does not identify deferiprone as a target product. The Texas HHS Commission's RFI HHS0017013 (response deadline April 3, 2026) explores direct-to-manufacturer prescription capability without specifying product categories. The code shows little relevant recent activity and likely represents a taxonomy mismatch rather than active state and local demand for deferiprone.